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Abstract
Background:  Depressive episodes in elderly patients with cerebrovascular damage are
characterized by poor responses to standard antidepressants. Recent reports have suggested that
the atypical antipsychotic, quetiapine may have antidepressant properties and, in mice, may
prevents memory impairment and hippocampus neurodegeneration induced by global cerebral
ischemia.
Objective: To evaluate the efficacy of combination therapy with quetiapine in depressed elderly
patients with cerebrovascular damage.
Methods: An open-label, 6-month follow-up study of patients with major depressive disorder
(DSM-IV) and cerebral abnormalities (assessed by MRI) without severe cognitive impairment.
Patients who had not responded to standard antidepressants (months of treatment 6.5 ± 7.2)
additionally received quetiapine (300 ± 111 mg/d). Patients were evaluated at baseline (t0) and
Months 1, 3, and 6 (t1, t3, t6) using the Clinical Global Impressions Scale for Severity (CGI-S) and
the Hamilton Depression Rating Scale (HAM-D).
Results: Nine patients were included in the study, with a mean age of 72.8 ± 9.4 years. CGI-S
scores decreased from baseline to Month 6: 5.8 ± 0.7 (t0), 5.4 ± 0.7 (t1), 5.0 ± 0.8 (t3), and 4.5 ±
1.0 (t6), with a significant improvement at 6 months compared with baseline (P = 0.006). A
significant improvement over the 6-month period was also observed with HAM-D scores (t0 = 27.2
± 4.0, t6 = 14.8 ± 3.8, P < 0.001).
Conclusion: In this study, quetiapine was efficacious as combination therapy in depressed elderly
patients with cerebrovascular damage. The promising results from this study warrant confirmation
in large, randomized, double-blind, placebo-controlled studies.
Introduction
A serious and common risk to the elderly is depression,
which, if untreated, is associated with a high rate of
relapse, an increased likelihood of chronicity, and an ele-
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vated rate of mortality [1]. Affective disorders (such as
depression) and vascular disease (including heart disease)
are frequently comorbid conditions that share certain eti-
opathogenetic and prognostic factors. If untreated,
depressive episodes may worsen the course of vascular
disease (particularly cerebrovascular diseases) and com-
promise both quality of life and lifespan expectation. The
close correlation between these comorbidities recently led
to the identification of so-called "vascular depression"
(Figure 1) [2].
Depressive episodes in elderly patients with cerebrovascu-
lar damage are characterized by low response rates to anti-
depressants, and it has therefore become increasingly
important to investigate new treatments [3]. However, few
therapeutic choices have been validated by strong clinical
evidence.
Quetiapine is an atypical antipsychotic approved for the
treatment of schizophrenia and episodes of mania associ-
ated with bipolar disorder. A lot of studies have also
described quetiapine monotherapy to be effective and
well tolerated in unipolar [4] and bipolar depression [5].
Recently was reported that quetiapine prevents memory
impairment and hippocampus neurodegeneration
induced by global cerebral ischemia in mice [6] and pre-
administration of quetiapine significantly alleviated the
depressive and anxiolytic-like behavioural changes
induced by global general ischemia in mice [7]. Authors
say that these results suggest a wider perspective for the
clinical use of quetiapine.
Nevertheless the US Food & Drug Administration (FDA)
advises there may be an increased risk of mortality
(mainly due to cardiovascular or infectious causes) in eld-
erly patients with dementia-related psychosis treated with
atypical antipsychotics.
Objective
To evaluate the effectiveness of quetiapine as add-on ther-
apy in elderly patients with late-onset depression and cer-
ebrovascular damage.
Methods
Study design
An open-label study of depressed elderly patients resistant
to ongoing treatments with cerebrovascular damage who
were observed for up to 6 months during add-on treat-
ment with quetiapine.
Study population
Elderly patients (>65 years of age), with a diagnosis of
Major Depressive Disorder (DSM-IV) [8] and cerebrovas-
cular damage documented by magnetic resonance imag-
ing (MRI), no cognitive impairment (Mini Mental State
Examination [MMSE] score <25) [9].
Clinical characteristics of vascular depression Figure 1
Clinical characteristics of vascular depression.
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Absence of psychotic symptoms or evident psychomotor
agitation.
No response to commonly prescribed antidepressants
(Hamilton Depression Rating Scale [HAM-D] score >18)
[10] following at least 3 months of treatment.
Written consent for the study was obtained after giving
patients a complete description of the study.
Study medication
Quetiapine was administered as add-on therapy with
commonly prescribed antidepressants (paroxetine, citalo-
pram, sertraline, mirtazapine).
Quetiapine therapy was initiated at a minimum daily
dose of 25 mg/d on Day 1 and was titrated up to 200 mg/
d on Day 7 according to the schedule shown in Table 1.
After Day 7, the dosage was increased by 100 mg every 2
days until the optimal dose, based on individual response
and tolerability, was reached.
Efficacy assessments
Efficacy was evaluated using the Clinical Global Impres-
sion-Severity scale (CGI-S) [11] and HAM-D rating scale
[10].
Patients were assessed at baseline (t0), and at the 1-month
(t1), 3-month (t3), and 6-month (t6) follow-up visits.
Statistical methods
Multivariate analysis of variance (MANOVA) was used to
test for differences in mean CGI-S and HAM-D scores over
time.
Results
Patient and treatment characteristics
Nine patients (6 females, 3 males) who had not
responded to standard antidepressants (mean [± SD] 6.5
± 7.2 months of treatment) were included in the study.
Patients had a mean age of 72.8 ± 6.4 years, a mean base-
line CGI-S score of 5.8 ± 0.7, and a mean baseline HAM-
D score of 27.2 ± 4.0.
Antidepressants administered in combination with
quetiapine are shown in Table 2. Other relevant medica-
tions taken were benzodiazepines (6 patients) and gabap-
entin (1 patient).
The mean quetiapine dose (SD) during the study was 300
± 111 mg/day.
Efficacy
During the period of add-on quetiapine treatment, CGI-S
scores improved significantly from a mean baseline (t0)
score of 5.8 ± 0.7 to 4.5 ± 1.0 at 6 months (t6) (F = 10.21,
P = 0.006; Table 3, Figure 2).
Reductions in mean HAM-D scores from baseline to
Month 6 were also statistically significant: t0 = 27.2 ± 4.0,
t6 = 14.8 ± 3.8, (F = 34.4, P < 0.001).
Tolerability
No patients discontinued the study.
Side effects reported by patients during the period of add-
on quetiapine treatment were sedation (2 patients) and
drowsiness (1 patient).
Discussion and conclusion
Add-on quetiapine therapy significantly improved depres-
sive symptoms and was well tolerated in these elderly
patients with comorbid depression and cerebrovascular
damage who had previously failed to respond to standard
antidepressants.
Although limited by its open-label design and small sam-
ple size, this study demonstrates the efficacy and tolerabil-
ity of quetiapine in this elderly patient population and is
consistent with our previous findings [12] and other pos-
itive studies of quetiapine in Bipolar Depression [5],
Table 3: Mean CGI-S scores during add-on quetiapine treatment
Evaluation time Mean score (SD)
Baseline (t0) 5.8 (0.7)
1 month (t1) 5.4 (0.7)
3 months (t3) 5.0 (0.8)
6 months (t6) 4.5 (1.0)
Table 1: Titration schedule
Day 1234567
Quetiapine 
dose (mg/d)
25 25 50 75 100 150 200
Table 2: Antidepressants used in combination with quetiapine*
Antidepressant Number of Patients
Paroxetine 3
Citalopram 3
Sertraline 1
Mirtazapine 2
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Major Depressive Disorder [4] and Generalized Anxiety
Disorder [13].
The results of a survey in mice suggest that quetiapine may
have defending effects on the impairments induced by
cerebral ischemia [6]. Another study shows that quetiap-
ine significantly attenuates bilateral common carotid
artery occlusion induced spatial memory impairment and
this improvement parallels the alleviative effects of
quetiapine on bilateral common carotid artery occlusion
induced neurodegeneration in the hilus of hippocampus
[7]. Quetiapine may have a neuroprotective and neuroge-
netic role and this may be related to the therapeutic effects
of quetiapine on cognitive deficits in patients with schiz-
ophrenia and depression, in which the structure and func-
tions of the hippocampus are implicated [6,7]. The
neuroprotective effect of quetiapine was recently con-
firmed in humans with bipolar disorders [14].
Quetiapine (with clozapine and risperidone) is the drug
most commonly used for treat behavioural problems of
dementia patients and do not seem to cause severe side
effects according to published data, thus may have a pos-
sible role in vascular depression [15-17].
These results require confirmation from large, rand-
omized, double-blind, placebo-controlled studies.
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Mean CGI-S scores in elderly patients with depressive epi- sodes and cerebrovascular damage during add-on quetiapine  therapy Figure 2
Mean CGI-S scores in elderly patients with depressive epi-
sodes and cerebrovascular damage during add-on quetiapine 
therapy.
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